Related Experiment Videos
Survey of pneumococcal types in Israel, 1978-81
Abstract:
The most common capsular types of Streptococcus pneumoniae that prevailed among 436 cultures isolated in Israel (1978 through 1981) were: 1, 14, 6B, 23F, 19A and 5. Among the 301 isolates from significant sources, 66.1% belonged to 14 capsular types that are included in available pneumococcal vaccines. Among those that were not included in these vaccines, the most frequent types were: 5, 19A and 6B. The addition of these three capsular polysaccharide types to the vaccine used in Israel would result in a vaccine coverage of approximately 85%.
Insights
Common Streptococcus pneumoniae types in Israel (1978-1981) included serotypes 1, 14, 6B, 23F, 19A, and 5. Adding types 5, 19A, and 6B to vaccines could increase coverage to 85%.
Area of Science:
- Microbiology
- Immunology
- Epidemiology
Background:
- Streptococcus pneumoniae causes significant morbidity and mortality globally.
- Pneumococcal vaccines are crucial for preventing invasive pneumococcal disease.
- Understanding prevalent serotypes is essential for optimizing vaccine efficacy.
Purpose of the Study:
- To identify the most common Streptococcus pneumoniae capsular types isolated in Israel between 1978 and 1981.
- To assess the potential vaccine coverage of existing and modified pneumococcal vaccines based on prevalent serotypes.
Main Methods:
- Analysis of 436 Streptococcus pneumoniae isolates from Israel (1978-1981).
- Serotyping of isolates to determine capsular types.
- Comparison of identified serotypes with those included in available pneumococcal vaccines.
Main Results:
- The most prevalent capsular types were 1, 14, 6B, 23F, 19A, and 5.
- 66.1% of 301 isolates from significant sources belonged to vaccine-included serotypes.
- Serotypes 5, 19A, and 6B were the most frequent among non-vaccine types.
Conclusions:
- The prevalent Streptococcus pneumoniae serotypes in Israel during 1978-1981 included several types not covered by contemporary vaccines.
- Inclusion of serotypes 5, 19A, and 6B in pneumococcal vaccines could significantly enhance vaccine coverage in Israel, potentially reaching approximately 85%.